Calliditas Therapeutics
Slipp dessa annonser och få en massa andra godsaker med vårt
premiumabonnemang.
New Drug Application Approval by the Pharmaceutical Administration Bureau of Macau for Nefecon® for the Treatment of Primary IgA Nephropathy
The NDA for Nefecon in mainland China is under Priority Review and Nefecon was the first non-oncology medicine to receive Breakthrough Therapy Designation in China. Nefecon has been available for clinical use in Shanghai Ruijin Hospital's Hainan subsidiary through an early-access program since April 2023.
| Datum | 2023-10-27, kl 09:15 |
| Källa | Cision |